Holen Sie sich die Stockscreener-App
4.19
1.18%
-0.05
Handel nachbörslich:
4.19
Schlusskurs vom Vortag:
$4.24
Offen:
$4.22
24-Stunden-Volumen:
1.52M
Relative Volume:
1.40
Marktkapitalisierung:
$519.05M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-1.4203
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
+1.45%
1M Leistung:
+7.16%
6M Leistung:
+18.36%
1J Leistung:
+147.93%
1-Tages-Spanne:
$4.025
$4.22
1-Wochen-Bereich:
$3.94
$4.41
52-Wochen-Spanne:
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.19 | 525.24M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics (ADCT) to Release Earnings on Tuesday - MarketBeat
ADC Therapeutics to Host Q4 2025 Financial Results Call - Intellectia AI
ADC Therapeutics (NYSE:ADCT) Sees Strong Trading VolumeHere's What Happened - MarketBeat
ADC Therapeutics delivers 70% return as Fair Value target hit - Investing.com
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ADCT: Pivotal data and new combinations position ZYNLONTA for major growth in lymphoma markets - TradingView
ADC Therapeutics sets March 10 call on 2025 results and operations - Stock Titan
ADCT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics Announces Upcoming Investor Conference Schedule - Intellectia AI
ADC Therapeutics to Participate in March Investor Conferences - Finviz
ADC Therapeutics amends royalty deal with HealthCare Royalty - Investing.com India
ADC Therapeutics (NYSE:ADCT) Shares Up 6.7%Time to Buy? - MarketBeat
ADC Therapeutics Amends HealthCare Royalty Financing Agreement - marketscreener.com
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement - GuruFocus
ADC Therapeutics Amends Royalty Deal, Issues New Warrants - TipRanks
ADC Therapeutics amends royalty deal with HealthCare Royalty By Investing.com - Investing.com Canada
ADC Therapeutics grants warrants to Healthcare Royalty By Investing.com - Investing.com Canada
Stepan Co recently released a project impact forecast, estimating that the cash impact over the entire project cycle will range between $29 million and $44 million, while the non-cash impact is expected to be between $58 million and $62 million. - Bitget
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027. - Bitget
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA. - Bitget
ADC Therapeutics SA announced that, in the event of a change of control, the acquirer will continue to pay royalties to the healthcare royalty company until the originally agreed cap amount is reached. - Bitget
ADC Therapeutics announces amended Healthcare Royalty Financing agreement - marketscreener.com
ADC Therapeutics grants warrants to Healthcare Royalty - Investing.com Australia
ADC Therapeutics Amends HCR Royalty Financing, Sets $150–$200 Million Change-of-Control Payment - TradingView
ADC Therapeutics (NYSE: ADCT) amends HCR royalty deal, adds warrants - Stock Titan
Analyst Calls: Is ADC Therapeutics SA affected by consumer sentimentWeekly Trade Recap & Daily Technical Stock Forecast Reports - baoquankhu1.vn
ADCT Should I Buy - Intellectia AI
Aug Patterns: Is CommScope Holding Company Inc stock undervalued right nowJuly 2025 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
ADC Therapeutics (ADCT) CMO granted 285,200-share RSU award, 24,603 withheld for taxes - Stock Titan
Redmile discloses 12.7% ADC Therapeutics (ADCT) ownership stake - Stock Titan
Has ADC Therapeutics (ADCT) outpaced other medical stocks this year? - MSN
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus
Will ADC Therapeutics SA stock sustain high P E ratiosMarket Activity Report & Risk Controlled Swing Trade Alerts - mfd.ru
What drives ADC Therapeutics SA’s stock priceJuly 2025 Setups & Growth Focused Investment Plans - mfd.ru
Can ADC Therapeutics SA stock deliver consistent earnings growth - mfd.ru
Can ADC Therapeutics SA deliver consistent dividends2025 Sector Review & Real-Time Volume Triggers - mfd.ru
Can ADC Therapeutics SA stock outperform in 2025 bull marketEarnings Miss & Safe Capital Growth Stock Tips - mfd.ru
Will ADC Therapeutics SA stock hit new highs in YEARQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - mfd.ru
Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50 - Defense World
Bond Watch: Is ADC Therapeutics SA a stock for growth or value investorsGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5%Here's Why - MarketBeat
ADC Therapeutics (NYSE:ADCT) Trading Down 4.5%Here's What Happened - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% – Here’s Why - Defense World
Little Excitement Around ADC Therapeutics SA's (NYSE:ADCT) Revenues - 富途牛牛
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking - simplywall.st
Update On ADCs: Sales, Deals, Targets And Approvals - Citeline News & Insights
ADC Therapeutics Grants Stock Options to New Employees - Intellectia AI
ADC Therapeutics (ADCT) upgraded to buy: Here's why - MSN
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):